Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Differential T and B Cell Responses to SARS-CoV-2 Vaccination in Multiple Sclerosis Patients Treated with Interferon β1-a or Ocrelizumab

  • By

  • Antonietta Liotti

  • Giorgia Teresa Maniscalco

  • Anne Lise Ferrara

  • Valeria Mazzone

  • Maedeh Dehbozorgi

  • Annamária Szabó

  • Martina Belardo

  • Daria Marcogiuseppe

  • Antonio De Martino

  • Maria Elena Di Battista

  • Giovanna Servillo

  • Ornella Moreggia

  • Daniele Di Giulio Cesare

  • Vincenzo Andreone

  • Gilda Varricchi

  • Veronica De Rosa

  • June 16, 2026

Share

Original Source(s)

Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine

  • by Antonietta Liotti, Giorgia Teresa Maniscalco, Anne Lise Ferrara, Valeria Mazzone, Maedeh Dehbozorgi, Annamária Szabó, Martina Belardo, Daria Marcogiuseppe, Antonio De Martino, Maria Elena Di Battista, Giovanna Servillo, Ornella Moreggia, Daniele Di Giulio Cesare, Vincenzo Andreone, Gilda Varricchi, Veronica De Rosa

  • June 16, 2026

Related Content

From Marginal to Central: Marginal Zone-like B Cells as Critical Targets in Cladribine-Treated Multiple Sclerosis

Self-efficacy as a mediator between health technology readiness and health-related quality of life: A survey study with mediation analysis

Association of therapeutic plasma exchange with functional outcomes in selected neurological disorders: a retrospective cohort study from a single tertiary center in Saudi Arabia